Diabetes Industry Veteran Pawel Fludzinski, Ph.D. assumed role of Company President of AmideBio

AmideBio LLC, a privately held biopharmaceutical company, announced today that Pawel Fludzinski, Ph.D. has assumed the role of Company President in addition to Chief Executive Officer, effective immediately. Dr. Misha Plam is retiring from the role but will remain Chairman of the Board of Directors. Read the full press release.

Diabetes Industry Veteran Pawel Fludzinski, Ph.D. Named CEO of AmideBio

AmideBio LLC, a privately held biopharmaceutical company, announced today that Dr. Pawel Fludzinski has joined the Company as its new Chief Executive Officer. With his extensive background in the development of drugs targeting diabetes at Eli Lilly & Co, Dr. Fludzinski was selected as the ideal candidate to lead AmideBio’s development of its pipeline of drug candidates targeting metabolic diseases. Read the full press release.

Charles A. Stanley MD, joins AmideBio’s Scientific Advisory Board

Charles A. Stanley MD joins AmideBio’s scientific advisory board to help further the Company’s soluble glucagon program for treating hyperinsulinism (HI). Dr. Stanley is a world-renowned expert on disorders of insulin regulation in children and founded the Congenital Hyperinsulinism Center at the Children’s Hospital of Philadelphia (CHoP). He helped define the various types of HI and has pioneered best practices for the diagnosis and treatment of congenital HI. Read the full press release.

Dr. David L. Snitman joins AMIDEBIO Business Advisory Board

Dr. Snitman who is a co-founder of Array BioPharma and served as Chief Operating Officer & Vice President, Business Development from 1998 to 2015 has joined AmideBio’s business advisory board. Read the full press release.

AMIDEBIO Closes $764,000 Equity Financing

AmideBio closed a new private placement round of $764,000 of preferred equity financing. The proceeds will be used to further the development of the Company’s pipeline of improved diabetes drug candidates, with particular focus on soluble glucagon for hyperinsulinism and glucose responsive insulin for diabetes

AMIDEBIO awarded NIH grant for hyperinsulinism program

AMIDEBIO has been awarded a $338,387 Phase 1 SBIR grant from the National Institute of Health to advance the company’s novel glucagon program for treating congenital hyperinsulinism.

AMIDEBIO granted E.U. Patent No. 2,787,083

AMIDEBIO has been granted European patent protection for novel peptide manufacturing process.

Boulder Peptide Symposium

AMIDEBIO CTO Dr. Michael Stowell will present a talk titled “Rapid-Recombinant SAR of Conformation Locked Insulin Analogs” at the 2016 Boulder Peptide Symposium Sept 26-29.

AMIDEBIO launches new website

To better serve our growing customer base AMIDEBIO has launched a new website with improved functionality and a better E-commerce experience.